儿童无关供者异基因造血干细胞移植中抗胸腺细胞球蛋白个体化给药(PARACHUTE):单臂2期临床试验
在荷兰乌得勒支两家中心开展的前瞻性单臂2期试验,58例儿童接受无关供者异基因造血干细胞移植,抗胸腺细胞球蛋白按体重、首次剂量前绝对淋巴细胞计数和干细胞来源个体化给药,累积剂量2-10 mg/kg。51例可评估患者中41例(80%,95%CI 67-90)达到CD4+免疫重建,研究达到主要终点,且未增加GVHD和植入失败发生率。
要点
- 个体化抗胸腺细胞球蛋白给药使51例可评估患者中41例(80%,95%CI 67-90)达到早期CD4+免疫重建。
- 脐血移植者CD4+免疫重建87%(95%CI 61-96),骨髓移植者77%(95%CI 54-89),两组差异无统计学显著(p=0.62)。
- 最常见的3-5级不良事件为感染(50%患者3级、3%患者4级、11%患者致死性事件)和免疫学疾病(11%患者3级、5%患者4级、8%患者致死性事件)。
核心结论
- 个体化抗胸腺细胞球蛋白给药显著改善早期CD4+免疫重建,且未增加GVHD和植入失败发生率。
- 通过个体化抗胸腺细胞球蛋白剂量促进早期CD4+免疫重建可能改善异基因造血干细胞移植的结局。
研究设计与样本
- 前瞻性、单臂、2期临床试验,在荷兰乌得勒支大学医学中心和Princess Máxima儿童肿瘤中心开展。
- 纳入58例18岁以下、首次接受T细胞去除移植物的异基因造血干细胞移植、Lansky/Karnofsky体能状态至少70%的患者。
- 抗胸腺细胞球蛋白剂量基于体重、首次剂量前绝对淋巴细胞计数和干细胞来源,累积剂量2-10 mg/kg。
- 主要终点为移植后100天(±3)内两次检测到CD4+ T细胞>0.05×10^9/L,需在53例可评估患者中38例达到。
主要发现
- 2015年7月1日至2018年8月22日纳入58例患者,其中51例可评估主要终点;中位随访25.6个月(IQR 15.0-37.0),中位年龄7.4岁(IQR 2.8-13.2),29例(50%)为女性。
- 51例可评估患者中41例(80%,95%CI 67-90,生存分析)达到CD4+免疫重建,研究达到主要终点。
- 脐血移植者CD4+免疫重建87%(95%CI 61-96),骨髓移植者77%(95%CI 54-89),差异无统计学显著(p=0.62)。
- 最常见的3-5级不良事件为感染(32例[50%]患者3级、2例[3%]患者4级、7例[11%]患者致死性事件)和免疫学疾病(7例[11%]患者3级、3例[5%]患者4级、5例[8%]患者致死性事件)。
- 64例患者中2例(3%)死于GVHD,可能与干预间接相关。
关键数值与推荐
- 主要终点:CD4+ T细胞>0.05×10^9/L在移植后100天(±3)内两次检测到。
- 抗胸腺细胞球蛋白累积剂量范围2-10 mg/kg,基于体重、首次剂量前绝对淋巴细胞计数和干细胞来源个体化确定。
- 入组要求Lansky/Karnofsky体能状态至少70%。
临床怎么用
- 作者认为,通过个体化抗胸腺细胞球蛋白剂量促进早期CD4+免疫重建可能改善异基因造血干细胞移植的结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anti-thymocyte globulin, which is used in the conditioning of haematopoietic stem-cell transplantation (HSCT) to prevent graft-versus-host disease (GVHD) and graft failure, has highly variable pharmacokinetics. Overexposure to anti-thymocyte globulin leads to poor CD4+ T-cell immune reconstitution, which is associated with inferior overall survival. We hypothesised that individualised anti-thymocyte globulin dosing would promote CD4+ immune reconstitution, while still preventing GVHD and graft failure. METHODS: We report the results of a prospective, single-arm, phase 2 clinical trial done at the University Medical Center Utrecht and the Princess Máxima Center for Pediatric Oncology (Utrecht, Netherlands) to investigate individualised dosing of anti-thymocyte globulin for unrelated allogeneic HSCT in paediatric patients. Anti-thymocyte globulin dosing was based on bodyweight, absolute lymphocyte counts before the first dose, and the stem-cell source, with cumulative doses ranging from 2-10 mg/kg. Patients younger than 18 years receiving a first HSCT with a T-cell repleted graft for any indication and a Lansky/Karnofsky performance status of at least 70% were eligible for inclusion. The primary endpoint was CD4+ immune reconstitution (>0·05 × 109 CD4+ T-cells per L twice within 100 days [±3] after transplantation). The primary endpoint needed to be met in 38 of 53 evaluable patients (no death, relapse, or graft failure before day 100). Toxicity was registered according to Common Terminology Criteria for Adverse Events criteria version 4.0. The study is registered with the Dutch Trial Register, NL4836. FINDINGS: Between July 1, 2015, and Aug 22, 2018, 58 patients were included in the study, of whom 51 were evaluable for the primary endpoint. Median follow-up was 25·6 months (IQR 15·0-37·0) and median age was 7·4 years (IQR 2·8-13·2). 29 (50%) of 58 patients were female. CD4+ immune reconstitution was reached in 41 (80%, 95% CI 67-90, in survival analysis) of 51 evaluable patients, hence the study met its primary endpoint. There was no difference in CD4+ immune reconstitution between patients who received different stem-cell sources (87% [95% CI 61-96] in cord blood, 77% [54-89] in bone marrow [p=0·62]). The most common grade 3-5 adverse events were infections (32 [50%] patients had grade 3, two [3%] patients had grade 4, and seven [11%] patients had fatal events) and immunological disorders (seven [11%] patients had grade 3, three [5%] patients had grade 4, and five [8%] patients had fatal events). Two (3%) of 64 patients died of GVHD, which might be indirectly related to the intervention. INTERPRETATION: Individualised dosing of anti-thymocyte globulin led to a significant improvement in early CD4+ immune reconstitution without increasing GVHD and graft failure incidence. Promotion of early CD4+ immune reconstitution by individualising anti-thymocyte globulin dose might improve outcomes of allogeneic HSCT. FUNDING: Sanofi.
引用
- Admiraal R, Nierkens S, Bierings MB, et al. Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial. Lancet Haematol. 2022. PMID: 35114150. doi:10.1016/S2352-3026(21)00375-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。